{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-015632","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.283925+00:00","generated_at":"2026-05-30T00:21:21.774160+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ProMIS Q3 net income $9.3M, cash $21.5M; Phase 1a positive; PIPE up to $122.7M","bullets":["Net income of $9.3M for Q3 2024 vs net loss of $2.4M YoY, driven by $17.0M gain on warrant liabilities.","Cash and equivalents $21.5M at Sep 30, 2024, up from $12.6M at Dec 31, 2023.","PIPE financing closed with initial $30.3M; potential additional $92.4M from warrant exercise.","Phase 1a trial of PMN310 in Alzheimer's showed good tolerability, dose-dependent BBB crossing, supporting monthly dosing.","Phase 1b clinical trial in AD patients on track to start by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-015632","json":"https://secwatch.observer/filing/0001558370-24-015632.json","markdown":"https://secwatch.observer/filing/0001558370-24-015632.md","text":"https://secwatch.observer/filing/0001558370-24-015632.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000155837024015632/0001558370-24-015632-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000155837024015632/pmn-20241114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:21:21.774160+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}